Journal Article
. 2012 Nov; 62(4):653-63.
doi: 10.1007/s00262-012-1370-x.

TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4(+)CD25 (+) Treg apoptosis

Zhijuan Diao 1 Juan Shi  Jieqing Zhu  Haiqin Yuan  Qiang Ru  Shilian Liu  Yanxin Liu  Dexian Zheng  
Affiliations
  • PMID: 23143747
  •     15 citations

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a promising and novel anticancer cytokine, specifically kills numerous tumor cells by apoptosis. However, some malignancies are resistant to TRAIL treatment in clinical trials, thus limiting its therapeutic potential. In the present study, the TRAIL-resistant murine hepatocellular carcinoma cell line Hepa1-6 was used to elucidate the physiological significance of TRAIL resistance, especially with respect to the immune regulatory function of TRAIL. Hepa1-6 cells were resistant to TRAIL-induced apoptosis in vitro; however, intratumoral injection of recombinant soluble TRAIL inhibited tumor growth and prolonged survival time in tumor-bearing mice. Local TRAIL treatment decreased the number of intratumoral CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) but did not affect CD4(+)CD25(+)Foxp3(+) Tregs in the draining lymph nodes and spleen. Further investigation showed that TRAIL induced apoptosis of tumor-activated CD4(+)CD25(+)Foxp3(+) Tregs, but not of CD4(+)CD25(-) T cells. Moreover, mouse TRAIL receptor DR5 expression was detected on the surface of the tumor-infiltrating CD4(+)CD25(+)Foxp3(+) Tregs, but not on naïve CD4(+)CD25(+)Foxp3(+) Tregs. Interestingly, intratumoral injection of TRAIL not only decreased the number of CD4(+)CD25(+)Foxp3(+) Tregs but also increased the number of tumor-specific CD8(+) CTL and augmented their cytotoxicity to the tumor cells. These data provide the novel evidence for an immune regulatory function of TRAIL and may shed light on the clinical application of TRAIL.

Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment.
Weifang Ling, Jimin Zhang, +7 authors, Yufang Shi.
Cancer Res, 2014 Jan 24; 74(5). PMID: 24452999    Free PMC article.
Highly Cited.
TRAIL deficiency contributes to diabetic nephropathy in fat-fed ApoE-/- mice.
Siân P Cartland, Jonathan H Erlich, Mary M Kavurma.
PLoS One, 2014 Mar 29; 9(3). PMID: 24667560    Free PMC article.
Effects of Treg cells and IDO on human epithelial ovarian cancer cells under hypoxic conditions.
Jun Liu, Haiyan Zhang, Luoqi Jia, Hong Sun.
Mol Med Rep, 2014 Nov 08; 11(3). PMID: 25376937    Free PMC article.
Tumor necrosis factor-related apoptosis-inducing ligand induces the expression of proinflammatory cytokines in macrophages and re-educates tumor-associated macrophages to an antitumor phenotype.
Jing Gao, Dongsheng Wang, +5 authors, Dexian Zheng.
Mol Biol Cell, 2015 Aug 01; 26(18). PMID: 26224317    Free PMC article.
Lactobacillus casei Exerts Anti-Proliferative Effects Accompanied by Apoptotic Cell Death and Up-Regulation of TRAIL in Colon Carcinoma Cells.
Angeliki Tiptiri-Kourpeti, Katerina Spyridopoulou, +12 authors, Katerina Chlichlia.
PLoS One, 2016 Feb 06; 11(2). PMID: 26849051    Free PMC article.
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy.
Silvia von Karstedt, Antonella Montinaro, Henning Walczak.
Nat Rev Cancer, 2017 May 26; 17(6). PMID: 28536452
Highly Cited. Review.
Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses.
Dong Sun Oh, Heegon Kim, +4 authors, Heung Kyu Lee.
Oncotarget, 2017 May 26; 8(29). PMID: 28537894    Free PMC article.
Arsenic trioxide and sorafenib combination therapy for human hepatocellular carcinoma functions via up-regulation of TNF-related apoptosis-inducing ligand.
Lingyan Wang, Zhihui Min, +5 authors, Yanhong Wang.
Oncol Lett, 2018 Aug 22; 16(3). PMID: 30127933    Free PMC article.
A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors.
Shuyong Zhang, Chao Zheng, +4 authors, Dexian Zheng.
Theranostics, 2019 Aug 15; 9(18). PMID: 31410224    Free PMC article.
Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy.
Margot de Looff, Steven de Jong, Frank A E Kruyt.
Front Immunol, 2019 Jul 25; 10. PMID: 31333662    Free PMC article.
Review.
Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia.
Zixuan Wang, Wenmo Liu, +8 authors, Xianghui Yu.
Signal Transduct Target Ther, 2020 Apr 25; 5(1). PMID: 32327638    Free PMC article.
Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer.
Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, +2 authors, Alejandro López-Soto.
Int J Mol Sci, 2020 May 30; 21(10). PMID: 32466293    Free PMC article.
Review.
TRAIL and FasL Functions in Cancer and Autoimmune Diseases: Towards an Increasing Complexity.
Aurélie Rossin, Giorgia Miloro, Anne-Odile Hueber.
Cancers (Basel), 2019 May 11; 11(5). PMID: 31072029    Free PMC article.
Review.
Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant.
Lisa C Holthof, Arwen Stikvoort, +8 authors, Tuna Mutis.
Hemasphere, 2021 Apr 27; 5(5). PMID: 33898931    Free PMC article.
Regulatory T Cell-Derived TRAIL Is Not Required for Peripheral Tolerance.
Rebekah E Dadey, Stephanie Grebinoski, +4 authors, Dario A A Vignali.
Immunohorizons, 2021 Jan 24; 5(1). PMID: 33483333    Free PMC article.